Gut Microbiome Shifts Linked to Alzheimer's Biomarkers Before Symptoms Appear
Key Insights
A study of 439 older adults found higher Akkermansia muciniphila levels associated with lower amyloid-beta accumulation in the brain, a key Alzheimer's hallmark.
Researchers identified 59 bacterial species linked to mild cognitive impairment or Alzheimer's, with closely related bacteria playing opposing roles in cognitive health.
A separate narrative review highlights that gut microbial dysregulation, including reduced SCFA-producing taxa, may begin during the preclinical stage of Alzheimer's before symptoms emerge.
A growing body of research is reshaping how scientists understand the origins of Alzheimer's disease (search), pointing toward the gut microbiome as a potentially critical player long before cognitive symptoms emerge. Two recent publications — one original study from Taiwan and one narrative review from Australia — add complementary evidence that microbial shifts in the digestive tract may be linked to the earliest biological hallmarks of Alzheimer's pathology.
Taiwanese Study Links Akkermansia muciniphila to Reduced Amyloid Burden
Researchers at National Yang Ming Chiao Tung University (NYCU) have demonstrated that older adults with higher levels of Akkermansia muciniphila — a next-generation probiotic increasingly recognized for its health benefits — show significantly lower levels of amyloid-beta accumulation in the brain. Published in Alzheimer's Research & Therapy, the study analyzed stool samples, Alzheimer's disease (search) biomarkers, and brain imaging data from 439 older adults.
Rather than grouping bacteria into broad taxonomic categories, the NYCU team used high-resolution genomic sequencing to identify microbes at the species level. This approach allowed researchers to distinguish subtle but potentially important biological differences. The analysis identified 59 bacterial species associated with either mild cognitive impairment or Alzheimer's disease (search). Notably, even closely related bacteria appeared to play different roles: some species were more abundant in cognitively healthy participants, while others were enriched in individuals with cognitive decline.
The researchers also found that these microbes operate as interconnected communities rather than in isolation. Interactions among bacterial species may alter key metabolic functions — including pathways involved in branched-chain amino acid biosynthesis — that are associated with amyloid accumulation and neurodegeneration. These findings suggest that the overall balance of the gut ecosystem, rather than any single bacterial species, may influence brain health.
"Although we observed a clear association between the gut microbiome and Alzheimer's biomarkers, the underlying biological mechanisms remain to be clarified," said Professor Yi-Fang Chuang of NYCU's Institute of Public Health, who led the study. "Future longitudinal studies will be needed to determine whether microbial changes contribute to disease progression or are themselves a consequence of neurodegeneration."
Chuang added that gut microbial composition varies considerably across populations because of differences in genetics, diet, and lifestyle. Consequently, findings from Western populations cannot always be generalized to Asian communities. By establishing one of Taiwan's most comprehensive datasets linking gut microbiomes, brain imaging, and Alzheimer's biomarkers, the study provides a valuable resource for future dementia research.
Review Highlights Preclinical Microbial Dysregulation
A separate narrative review published in the journal Nutrients, conducted by researchers across Australia, synthesized existing evidence on gut microbiota, microbial metabolites, and dietary patterns in relation to early Alzheimer's disease (search). The review did not generate or analyze new data but highlighted important patterns emerging from the literature.
The review notes that Alzheimer's disease (search) has a long preclinical stage during which metabolic alterations, amyloid accumulation, and neuroinflammation develop while people remain cognitively unimpaired. Understanding these biological changes can help elucidate mechanisms pertinent to early prevention.
A growing body of research suggests that Alzheimer's is associated with changes in gut microbiota function and composition. In particular, reduced abundance of short-chain fatty acid (SCFA)-producing genera — such as Eubacterium, Roseburia, and Faecalibacterium — has been commonly reported in Alzheimer's and cognitive impairment. Meanwhile, some studies report an increased relative abundance of Escherichia/Shigella and other Proteobacteria, which are associated with inflammatory signaling, metabolic imbalance, and oxidative stress.
Early changes in microbial metabolic pathways and SCFA-producing taxa have been reported in a small number of studies involving cognitively unimpaired individuals with biomarker evidence of amyloid pathology. Although studies have reported inconsistent findings, they suggest that the earliest stages of Alzheimer's may be characterized by gut microbial dysregulation.
Diet as a Modifiable Factor
The Australian review also examined dietary patterns associated with Alzheimer's risk. The Dietary Approaches to Stop Hypertension (DASH) diet and the Mediterranean diet are associated with improved cognitive, cardiovascular, and metabolic outcomes in aging populations. Both emphasize increased intake of plant-based foods while limiting processed and red meats, added sugars, and saturated fats. Higher adherence to these diets is linked to reduced cerebral amyloid burden, slower cognitive decline, and improved vascular function in older individuals.
The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, which combines elements from both DASH and Mediterranean diets, has similarly been associated with slower accumulation of Alzheimer's-related pathology. The prudent dietary pattern — characterized by high intake of fruits, whole grains, vegetables, fish, low-fat dairy, and legumes — has been associated with higher microbial diversity and enrichment of SCFA-producing taxa.
Therapeutic Context and Limitations
Current Alzheimer's treatments offer limited benefit once cognitive decline is established. Common symptomatic treatments, including memantine, donepezil, galantamine, and rivastigmine, provide modest cognitive and functional improvements. While disease-modifying therapies such as lecanemab have been developed for early-stage Alzheimer's, they are restricted to select populations and have limited clinical benefit. Most available treatments are initiated only after substantial damage has occurred, underscoring the need for research focused on earlier disease stages.
Both publications acknowledge important limitations in the current evidence base. Most studies have involved populations with Alzheimer's or mild cognitive impairment rather than biomarker-confirmed preclinical Alzheimer's, and much of the available evidence is cross-sectional, preventing conclusions about the direction of the relationship. Sequencing has generally been limited to the genus level, and few studies have jointly assessed diet, gut microbiota, microbial functional pathways, SCFAs, and amyloid pathology.
The NYCU study and the Australian review together open new possibilities for developing microbiome-based strategies to predict, prevent, and potentially slow the progression of Alzheimer's disease (search) — though both research groups emphasize that much work remains before such approaches reach clinical application.